Evercore ISI Covers Dicerna Pharma (DRNA) with $14.0 Target; Prosperity Bancshares (PB) Sellers Decreased By 2.79% Their Shorts

January 16, 2018 - By Migdalia James

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals has $30 highest and $3.50 lowest target. $9.88’s average target is 12.40% above currents $8.79 stock price. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, November 11. Cowen & Co maintained the shares of DRNA in report on Tuesday, July 18 with “Buy” rating. The rating was maintained by Chardan Capital Markets on Thursday, June 30 with “Neutral”. As per Tuesday, September 8, the company rating was initiated by Cowen & Co. Leerink Swann reinitiated the stock with “Mkt Perform” rating in Tuesday, January 31 report. The rating was maintained by Stifel Nicolaus on Tuesday, May 10 with “Buy”. As per Wednesday, August 16, the company rating was maintained by Cowen & Co. The firm has “Buy” rating given on Monday, December 12 by H.C. Wainwright. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, November 2. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, June 30.

Prosperity Bancshares Incorporated (NYSE:PB) had a decrease of 2.79% in short interest. PB’s SI was 4.27 million shares in January as released by FINRA. Its down 2.79% from 4.40M shares previously. With 270,800 avg volume, 16 days are for Prosperity Bancshares Incorporated (NYSE:PB)’s short sellers to cover PB’s short positions. The SI to Prosperity Bancshares Incorporated’s float is 6.47%. The stock decreased 0.07% or $0.05 during the last trading session, reaching $74.93. About 25,904 shares traded. Prosperity Bancshares, Inc. (NYSE:PB) has risen 27.06% since January 16, 2017 and is uptrending. It has outperformed by 10.36% the S&P500.

Among 19 analysts covering Prosperity Bancshares (NYSE:PB), 4 have Buy rating, 5 Sell and 10 Hold. Therefore 21% are positive. Prosperity Bancshares had 50 analyst reports since July 28, 2015 according to SRatingsIntel. Bank of America downgraded the stock to “Underperform” rating in Tuesday, January 12 report. The rating was maintained by Stephens on Wednesday, July 26 with “Hold”. Robert W. Baird maintained it with “Hold” rating and $74.0 target in Wednesday, January 10 report. The stock of Prosperity Bancshares, Inc. (NYSE:PB) has “Underweight” rating given on Wednesday, November 16 by Morgan Stanley. The firm has “Hold” rating by Keefe Bruyette & Woods given on Thursday, December 21. The stock of Prosperity Bancshares, Inc. (NYSE:PB) has “Hold” rating given on Tuesday, October 3 by Keefe Bruyette & Woods. As per Friday, April 28, the company rating was downgraded by Wood. The stock has “Mkt Perform” rating by FBR Capital on Tuesday, July 28. Hovde Group downgraded Prosperity Bancshares, Inc. (NYSE:PB) on Friday, November 18 to “Market Perform” rating. The stock of Prosperity Bancshares, Inc. (NYSE:PB) has “Buy” rating given on Tuesday, October 31 by SunTrust.

Prosperity Bancshares, Inc. operates as bank holding firm for the Prosperity Bank that provides a range of retail and commercial banking services to small and medium-sized businesses, and consumers. The company has market cap of $5.21 billion. The firm offers various deposit products, including demand, savings, money market, and time accounts. It has a 19.02 P/E ratio. It also provides one to four family residential mortgage loans, commercial mortgage and multifamily residential loans, commercial and industrial loans, agricultural real estate loans, and non-real estate agricultural loans, as well as construction, land development, and other land loans; consumer loans, such as automobile, recreational vehicle, boat, home improvement, personal, and deposit account collateralized loans; and consumer durables and home equity loans, as well as debit and credit cards.

Since December 18, 2017, it had 1 insider purchase, and 0 selling transactions for $2.00 million activity. On Monday, December 18 Bain Capital Life Sciences Investors – LLC bought $2.00 million worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 285,000 shares.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $453.93 million. The company??s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Investors sentiment increased to 0.79 in 2017 Q3. Its up 0.24, from 0.55 in 2017Q2. It is positive, as 9 investors sold Dicerna Pharmaceuticals, Inc. shares while 10 reduced holdings. 8 funds opened positions while 7 raised stakes. 10.37 million shares or 6.06% less from 11.04 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Connor Clark & Lunn Mgmt holds 0% or 68,975 shares in its portfolio. Jpmorgan Chase & accumulated 1,600 shares or 0% of the stock. Millennium Mngmt Limited Liability stated it has 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Morgan Stanley holds 0% or 1,189 shares in its portfolio. Ecor1 Cap Llc holds 957,992 shares or 0.73% of its portfolio. Goldman Sachs Grp Inc Inc accumulated 0% or 105,420 shares. Barclays Pcl reported 0% stake. California Public Employees Retirement reported 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bank & Trust Of America De invested in 397 shares or 0% of the stock. The Connecticut-based Bourgeon Cap Limited Company has invested 0.11% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Virtu Fincl Limited Liability Corporation has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dimensional Fund Advsr Limited Partnership holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 27,342 shares. 469,600 were reported by Renaissance Tech Limited Com. Ra Capital Lc stated it has 1.26% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

The stock increased 4.39% or $0.37 during the last trading session, reaching $8.79. About 55,650 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since January 16, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: